A mutation update on the LDS-associated genesTGFB2/3andSMAD2/3
Open Access
- 1 February 2018
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 39 (5), 621-634
- https://doi.org/10.1002/humu.23407
Abstract
The Loeys–Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular system. Most typically, LDS patients present with aortic aneurysms and arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate. Initially, mutations in transforming growth factor‐β (TGF‐β) receptors (TGFBR1 and TGFBR2) were described to cause LDS, hereby leading to impaired TGF‐β signaling. More recently, TGF‐β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF‐β pathway, SMAD2 and SMAD3, were shown to be involved in LDS. This emphasizes the role of disturbed TGF‐β signaling in LDS pathogenesis. Since most literature so far has focused on TGFBR1/2, we provide a comprehensive review on the known and some novel TGFB2/3 and SMAD2/3 mutations. For TGFB2 and SMAD3, the clinical manifestations, both of the patients previously described in the literature and our newly reported patients, are summarized in detail. This clearly indicates that LDS concerns a disorder with a broad phenotypical spectrum that is still emerging as more patients will be identified. All mutations described here are present in the corresponding Leiden Open Variant Database.Funding Information
- Universiteit Antwerpen
- Hartstichting (2013T093)
- Fondation Leducq (12CVD03)
- Fonds Wetenschappelijk Onderzoek (G.0356.17)
- H2020 European Research Council (ERC-StG-2012-30972-BRAVE)
This publication has 88 references indexed in Scilit:
- Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysmNature Genetics, 2012
- Lessons on the pathogenesis of aneurysm from heritable conditionsNature, 2011
- Clinical utility gene card for: Loeys-Dietz syndrome (TGFBR1/2) and related phenotypesEuropean Journal of Human Genetics, 2011
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- TRAF6 Mediates Smad-Independent Activation of JNK and p38 by TGF-βMolecular Cell, 2008
- TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcAThe EMBO Journal, 2007
- Fibrillin-1 regulates the bioavailability of TGFβ1The Journal of cell biology, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003